2seventy bio (2seventy bio) Gross Profit : $54.08 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Gross Profit?

2seventy bio's gross profit for the three months ended in Mar. 2024 was $7.94 Mil. 2seventy bio's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $54.08 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. 2seventy bio's gross profit for the three months ended in Mar. 2024 was $7.94 Mil. 2seventy bio's Revenue for the three months ended in Mar. 2024 was $12.44 Mil. Therefore, 2seventy bio's Gross Margin % for the quarter that ended in Mar. 2024 was 63.82%.

2seventy bio had a gross margin of 63.82% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 6 years, the highest Gross Margin % of 2seventy bio was 98.38%. The lowest was 59.82%. And the median was 88.22%.

Warning Sign:

2seventy bio Inc gross margin has been in long-term decline. The average rate of decline per year is -5.9%.

2seventy bio Gross Profit Historical Data

The historical data trend for 2seventy bio's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Gross Profit Chart

2seventy bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

41.32

242.73

32.61

65.28

83.47

2seventy bio Quarterly Data
	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Profit	Get a 7-Day Free Trial													37.33	31.53	7.08	7.54	7.94

Competitive Comparison of 2seventy bio's Gross Profit

For the Biotechnology subindustry, 2seventy bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

2seventy bio's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2seventy bio's Gross Profit distribution charts can be found below:

* The bar in red indicates where 2seventy bio's Gross Profit falls into.

2seventy bio Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

2seventy bio's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	100.387	-	16.918
	=	83.47

2seventy bio's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )	=	Revenue	-	Cost of Goods Sold
	=	12.435	-	4.499
	=	7.94

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $54.08 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

2seventy bio's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	7.94	/	12.435
	=	63.82 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

2seventy bio (NAS:TSVT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

2seventy bio had a gross margin of 63.82% for the quarter that ended in Mar. 2024 => Durable competitive advantage

2seventy bio Gross Profit Related Terms

Thank you for viewing the detailed overview of 2seventy bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

2seventy bio (2seventy bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.2seventybio.com

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Executives

Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory	officer: Chief Scientific Officer	POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii	officer: Chief Financial Officer	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Lin Wei	director	C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron	officer: Chief Operating Officer	2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus	director	16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch	director
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938